Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation


Record Status
This is an economic evaluation that meets the criteria for inclusion on NHS EED.

Bibliographic details

PubMedID
20646668

DOI
10.3310/hta14360

Indexing Status
Subject indexing assigned by NLM

MeSH
Adamantane /analogs & derivatives /economics /therapeutic use; Body Weight /drug effects; Cost-Benefit Analysis; Diabetes Mellitus, Type 2 /drug therapy; Dipeptidyl-Peptidase IV Inhibitors /economics /therapeutic use; Glucagon-Like Peptide 1 /analogs & derivatives; Great Britain; Hemoglobin A, Glycosylated /drug effects; Humans; Hypoglycemic Agents /adverse effects /economics /therapeutic use; Insulin /analogs & derivatives /economics /therapeutic use; Insulin Glargine; Insulin, Long-Acting; Nitriles /economics /therapeutic use; Peptides /economics /therapeutic use; Pyrazines /economics /therapeutic use; Pyrrolidines /economics /therapeutic use; Quality of Life; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; State Medicine; Thiazolidinediones /economics /therapeutic use; Triazoles /economics /therapeutic use; Venoms /economics /therapeutic use

AccessionNumber
22010001427

Date bibliographic record published
17/11/2010